STAMFORD, Conn., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. CARA, a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced a late-breaking oral presentation and two posters on KORSUVA™ (CR845/difelikefalin) Injection will be presented at Kidney Week 2019, the American Society of Nephrology's Annual Meeting, to be held November 5-10, 2019, in Washington, DC.
The late-breaking oral presentation will include data from KALM-1, the pivotal Phase 3 clinical trial of KORSUVA Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP), and the posters will include data from the Phase 2 trial of KORSUVA Injection in the same patient population. KORSUVA Injection is Cara's first-in-class drug candidate designed to target kappa opioid receptors in the body's peripheral nervous system, as well as certain immune cells.
Details for the presentations are as follows:
Late-Breaking Oral Presentation:
Title: Efficacy and Safety of Difelikefalin in Patients Undergoing Hemodialysis With Pruritus: Results From a Phase 3 Randomized, Controlled Study (KALM-1)
Abstract Number: FR-OR134
Date / Time: Friday, November 8, 2:45 to 3 p.m. ET
Presenter: Steven Fishbane, MD, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Poster Presentations:
Title: Difelikefalin Improved Quality of Life (5-D Itch Scale-Domains) in Hemodialysis Patients With Pruritus in an 8-Week Phase 2 Randomized, Placebo-Controlled Study
Poster Number: TH-PO245
Date / Time: Thursday, November 7, 10 a.m. to 12 p.m.
Presenter: Robert Spencer, Cara Therapeutics
Title: Difelikefalin Significantly Reduced Sleep Disturbance in Hemodialysis Patients With Moderate-to-Severe Pruritus in an 8-Week Phase 2, Randomized, Placebo-Controlled Study
Poster Number: TH-PO247
Date / Time: Thursday, November 7, 10 a.m. to 12 p.m. ET
Presenter: Sarbani Bhaduri, MD, Cara Therapeutics
For more information about Kidney Week 2019, visit https://www.asn-online.org/education/kidneyweek/.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells. In both Phase 3 and Phase 2 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). KORSUVA Injection is currently being investigated in pivotal Phase 3 trials in hemodialysis patients with CKD-aP. Oral KORSUVA is in Phase 2 trials for the treatment of pruritus in patients with CKD, atopic dermatitis and primary biliary cholangitis (PBC).
The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
INVESTOR CONTACT:
Jane Urheim
Stern Investor Relations, Inc.
212-362-1200
Jane.Urheim@SternIR.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.